GE HealthCare Technologies Inc. GEHC

Nasdaq; healthcare; SIC 3844, X-Ray Apparatus & Tubes & Related Irradiation Apparatus; CIK 0001932393

B

second fifth of 370 graded peers in healthcare

rank 96 of 370; percentile 25.7; sampling error 2.5 points; lower is stronger


A B C D E

B, the elk




Scoreboard	
Profitability	C/D percentile 59.2
Solvency	C percentile 43.1
Growth and financing	A percentile 16.0
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $36.9B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Feb 4, 2026 264 days before the rescan; latest periodic filing 10-Q received Jul 29, 2026
Last close	$71.45 2026-10-23; market equity $32.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 4, 2026

GE HealthCare Technologies Inc. ("GE HealthCare," the "Company," "our," "us," or "we") is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. We have approximately 54,000 colleagues dedicated to our purpose to create a world where healthcare has no limits. Serving patients and providers for nearly 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine to help clinicians deliver more personalized, precise patient care.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 59.2						
Gross profitability	22.3%	32.3%		60.8	368	2025-12-31
Return on invested capital	14.1%	9.3%		35.6	74	2025-12-31
Accruals ratio	0.3%	(6.6%)		81.3	807	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 3						
Solvency, sleeve percentile 43.1						
Twelve-month failure probability	not computable	0.07%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	1.99	(0.33)		29.0	752	2025-12-31
Net debt to EBITDA	1.81x	1.82x		50.0	75	2025-12-31
Interest coverage	6.28x	(4.51x)		10.0	81	2025-12-31
Current ratio	1.37x	2.94x		83.2	834	2025-12-31
Growth and financing, sleeve percentile 16.0						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 3						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	150.8%	37.1%		21.4	104	2025-12-31
Asset growth, three years	not computable	2.1%				
four annual observations are required; found 3						
Net share issuance, one year	(0.3%)	2.5%		10.6	636	2026-01-28

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
91	Pulmonx Corp. (LUNG)	24.4	B	fortress balance sheet
92	Amphastar Pharmaceuticals, Inc. (AMPH)	24.7	B	
93	Mannatech Inc. (MTEX)	24.9	B	late filer, fortress balance sheet
94	Mirum Pharmaceuticals, Inc. (MIRM)	25.2	B	
95	NeuroPace Inc. (NPCE)	25.5	B	
96	GE HealthCare Technologies Inc. (GEHC)	25.7	B	
97	Phibro Animal Health Corp. (PAHC)	26.0	B	
98	Lineage Cell Therapeutics, Inc. (LCTX)	26.3	B	
99	Zoetis Inc. (ZTS)	26.6	B	
100	Sensus Healthcare, Inc. (SRTS)	26.8	B	
101	Travere Therapeutics, Inc. (TVTX)	27.1	B	

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(5.0%)	7.7%	43
Distance from 52-week high	(19.0%)	(31.4%)	64
EBIT to enterprise value	6.8%	(1.5%)	85
Free cash flow yield	4.6%	(1.0%)	82
Book value to price	0.33	0.28	55

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.63	0.30	72
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.26)	(0.14)	43

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$2.3B
Operating cash flow, four quarters	$2.0B
Months of runway	not finite
Days since last periodic filing	89 (10-Q received Jul 29, 2026)
Median daily dollar volume, 63 sessions	$217.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$8.2B	2025-12-31	2026-02-04	10-K	26-000007
2	assets	us-gaap:Assets	$36.9B	2025-12-31	2026-02-04	10-K	26-000007
3	operating income	us-gaap:OperatingIncomeLoss	$2.8B	2025-12-31	2026-02-04	10-K	26-000007
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$2.8B	2025-12-31	2026-02-04	10-K	26-000007
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$614.0M	2025-12-31	2026-02-04	10-K	26-000007
6	total debt	us-gaap:LongTermDebt	$10.0B	2025-12-31	2026-02-04	10-K	26-000007
7	book equity	us-gaap:StockholdersEquity	$10.4B	2025-12-31	2026-02-04	10-K	26-000007
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$4.5B	2025-12-31	2026-02-04	10-K	26-000007
9	total debt	us-gaap:LongTermDebt	$9.0B	2024-12-31	2026-02-04	10-K	26-000007
10	book equity	us-gaap:StockholdersEquity	$8.4B	2024-12-31	2026-02-04	10-K	26-000007
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$2.9B	2024-12-31	2026-02-04	10-K	26-000007
12	net income	us-gaap:NetIncomeLoss	$2.1B	2025-12-31	2026-02-04	10-K	26-000007
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesC...	$2.0B	2025-12-31	2026-02-04	10-K	26-000007
14	assets	us-gaap:Assets	$33.1B	2024-12-31	2026-02-04	10-K	26-000007
15	current assets	us-gaap:AssetsCurrent	$12.5B	2025-12-31	2026-02-04	10-K	26-000007
16	current liabilities	us-gaap:LiabilitiesCurrent	$9.1B	2025-12-31	2026-02-04	10-K	26-000007
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$5.3B	2025-12-31	2026-02-04	10-K	26-000007
18	liabilities	us-gaap:Liabilities	$26.3B	2025-12-31	2026-02-04	10-K	26-000007
19	depreciation amortization	us-gaap:Depreciation	$287.0M	2025-12-31	2026-02-04	10-K	26-000007
20	interest expense	us-gaap:InterestAndDebtExpense	$440.0M	2025-12-31	2026-02-04	10-K	26-000007
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$20.6B	2025-12-31	2026-02-04	10-K	26-000007
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$19.7B	2024-12-31	2026-02-04	10-K	26-000007
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$19.6B	2023-12-31	2026-02-04	10-K	26-000007
24	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$482.0M	2025-12-31	2026-02-04	10-K	26-000007
25	current assets	us-gaap:AssetsCurrent	$9.9B	2024-12-31	2026-02-04	10-K	26-000007
26	current liabilities	us-gaap:LiabilitiesCurrent	$9.6B	2024-12-31	2026-02-04	10-K	26-000007
27	assets	us-gaap:Assets	$32.5B	2023-12-31	2025-02-13	10-K	25-000005

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	shares outstanding	dei:EntityCommonStockSharesOutstanding	455,749,767	2026-01-28	2026-02-04	10-K	26-000007
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	457,298,310	2025-02-06	2025-02-13	10-K	25-000005